You searched for "therapeutics"
Sustained elevation of extracellular ATP in chronic glaucoma
Although adenosine 5′-triphosphate (ATP) release from retinal neurons and astrocytes has been demonstrated in short-term increases in intraocular pressure (IOP); such as in aqueous humor of humans with primary acute angle closure glaucoma, the response in chronic IOP elevation was...
ANGPTL-4 inhibition reduces inflammation in diabetic retinopathy
Diabetic retinopathy (DR) is the most common cause of blindness in working-age humans, and numbers are rising due to increased cases of type 2 diabetes (T2D). T2D is associated with increased obesity and dyslipidaemia, which is a major risk factor...
A mouse model for uveal melanoma
Uveal melanoma (UM) is the most common malignant tumour arising within the eye and is a severe threat for both sight and life, due to a high risk of metastasis. There are no animal models of UM, but the Tg(Grm1)...
MicroRNA mediate retinoblastoma signal transduction
MicroRNAs (miR) are small non-coding single-stranded RNA molecules, normally 22 nucleotides long. There is a large family of miR that control protein expression by binding to mRNAs, leading to their degradation. One important role of miR is in tumours where...
MicroRNA inhibits corneal neovascularisation
MicroRNAs (miR) are small non-coding RNA that target mRNA for destruction. MiR target about 30% of the protein coding genes and fine tune their expression. MiR have been shown to be involved in several cellular processes including cell cycle, tissue...
Rituximab as an immunosuppression treatment for thyroid eye disease
Thyroid eye disease is traditionally treated with high dose glucocorticosteroids and surgical orbital decompression, where responses are often inadequate. This medical treatment is centred around symptom control and reduction of thyroid hormone synthesis, not immunosuppression. Rituximab is an anti-CD20 monoclonal...
Differential diagnosis of inflammatory optic neuritis
The authors present the differential diagnosis of inflammatory optic neuritis (ON) to include multiple sclerosis, infectious optic neuritis, systemic disease and neuromyelitis optica (NMO). The features of ON for the varying aetiologies are detailed including incidence and overlap. In acute...
Steroid safety in MG treatment
This study was conducted to evaluate the efficacy and safety of low to moderate dose oral steroids in patients diagnosed with ocular myasthenia gravis (MG). This was a retrospective case series. The study reviewed 23 patients; 15 males and eight...
Investigating MOG-IgG as a cause for optic perineuritis
Optic perineuritis can be a manifestation of infectious and systemic inflammatory disorders, but in most cases is considered idiopathic. Diagnosis is established by magnetic resonance imaging (MRI) with the demonstration of optic nerve sheath enhancement with sparing of the optic...
A pulsatile pump in the TM, a new concept in trabecular outflow research
This is a research article where the authors propose a new model in conceptualising the mechanisms involved in the aqueous outflow at the trabecular meshwork (TM). The authors demonstrated evidence of a pump within the Schlemm’s canal. A pulse generated...
Therapeutic options for advanced cutaneous basal (BCC) and squamous cell carcinomas (SCC)
This article discusses the use of topical and systemic therapy in the management of advanced periocular tumours. It focuses on those that have gained United States Food and Drug Administration approval; namely imiquimod, vismodegib, sonidegib, pembrolizumab and cemiplimab. Imiquimod is...
